{
  "meta": {
    "title": "62_Acid_Peptic_Disorders_And_Inflammatory_Bowel_Disease",
    "url": "https://brainandscalpel.vercel.app/62-acid-peptic-disorders-and-inflammatory-bowel-disease-9197e356.html",
    "scrapedAt": "2025-11-30T12:34:40.415Z"
  },
  "questions": [
    {
      "text": "The final step in gastric acid production is inhibited by:",
      "choices": [
        {
          "id": 1,
          "text": "H2 blockers"
        },
        {
          "id": 2,
          "text": "Proton pump inhibitors"
        },
        {
          "id": 3,
          "text": "Octreotide"
        },
        {
          "id": 4,
          "text": "Antimuscarinics"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>final step</strong> in gastric<strong> acid production</strong> is <strong>inhibited</strong> by the <strong>proton pump inhibitors</strong> (PPIs).</p>\n<p>The <strong>secretion</strong> of<strong> protons</strong> by the activated <strong>H<sup>+</sup>/K<sup>+</sup>- ATPase</strong> (proton pump) in the <strong>parietal cells</strong> into the gastric lumen is the <strong>final step</strong> involved in the production of<strong> gastric acid</strong>.&nbsp;</p>\n<p>PPIs cause <strong>maximum suppression</strong> of gastric acid and also <strong>reduces basal acid secretion.</strong> Suppression of gastric acid occurs regardless of the stimulus present.&nbsp;&nbsp;</p><img src=\"https://cdn1.dailyrounds.org/uploads/79f8d7a356254942ac77ef98dbd915b6x912x630.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6518",
      "difficulty": "easy"
    },
    {
      "text": "Despite their short half-lives, how do proton-pump inhibitors cause prolonged suppression of acid secretion for up to 48 hours?",
      "choices": [
        {
          "id": 1,
          "text": "Prodrugs and undergo activation gradually"
        },
        {
          "id": 2,
          "text": "Exit from plasma and enter acid secretory canaliculi, blocking the secretion of acid for a long time"
        },
        {
          "id": 3,
          "text": "Irreversibly inhibit proton pump molecule, acid secretion requires synthesis of new proton pumps"
        },
        {
          "id": 4,
          "text": "Available as enteric coated capsules from which drug is gradually released"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>PPIs irreversibly inhibit</strong> the<strong> proton pump</strong> molecule and hence, acid secretion requires the synthesis of new proton pumps.</p>\n<p>PPIs are<strong> prodrugs</strong>, when ingested, get <strong>absorbed</strong> into the <strong>systemic</strong> circulation. It then <strong>diffuses</strong> into the <strong>parietal cells </strong>of the stomach and accumulates in the acidic secretory canaliculi. <strong>Acidic pH </strong>in the parietal cell canaliculi causes <strong>activation</strong> of the PPIs. These activated PPIs irreversibly inhibit H<sup>+</sup>/K<sup>+</sup> ATPase (proton pump) in the parietal cell.</p>\n<p>The maximum proton pump activation corresponds to the peak concentration of PPI resulting in maximum efficacy.</p>\n<p>The secretion resumes gradually over 3-4 days of stopping the drug when new proton pumps are synthesized.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6521",
      "difficulty": "easy"
    },
    {
      "text": "A patient with gastroesophageal reflux disease was prescribed an oral PPI preparation that causes the fastest acid suppression. Identify the drug.",
      "choices": [
        {
          "id": 1,
          "text": "Dexlansoprazole"
        },
        {
          "id": 2,
          "text": "Esomeprazole"
        },
        {
          "id": 3,
          "text": "Pantoprazole"
        },
        {
          "id": 4,
          "text": "Rabeprazole"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Rabeprazole </strong>is the&nbsp;oral PPI preparation that causes the <strong>fastest acid suppression</strong>. It has a <strong>higher pKa</strong> that causes more <strong>rapid conversion</strong> to active species in acidic canaliculi.&nbsp;</p>\n<p>The efficacy and potency are similar to that of omeprazole.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1312",
      "difficulty": "medium"
    },
    {
      "text": "A neighbor approaches you for advice on the best time to take pantoprazole for heartburn. What would you recommend?",
      "choices": [
        {
          "id": 1,
          "text": "After meals"
        },
        {
          "id": 2,
          "text": "Shortly before meals"
        },
        {
          "id": 3,
          "text": "Along with milk"
        },
        {
          "id": 4,
          "text": "During meals"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Proton-pump inhibitors </strong>(pantoprazole) should be ideally given shortly (20-30 minutes)<strong> before food</strong>.</p>\n<p>PPIs are usually given before breakfast.&nbsp;Food hinders the absorption of PPIs and decreases their bioavailability.</p>\n<p>PPIs are <strong>prodrugs</strong>, when ingested, get absorbed into the systemic circulation. It then diffuses into the parietal cells of the stomach and accumulates in the acidic secretory canaliculi. <strong>Acidic pH </strong>in the parietal cell canaliculi causes <strong>activation</strong> of the PPIs.&nbsp;The maximum proton pump activation corresponds to the peak concentration of PPI resulting in maximum efficacy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6523",
      "difficulty": "easy"
    },
    {
      "text": "A patient undergoing evaluation for multiple gastroduodenal ulcers was diagnosed with Zollinger-Ellison syndrome. What would be the drug of choice for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Proton pump inhibitors"
        },
        {
          "id": 2,
          "text": "H2 blockers"
        },
        {
          "id": 3,
          "text": "Sucralfate"
        },
        {
          "id": 4,
          "text": "Prostaglandin analogs"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Proton-pump inhibitors </strong>are the drug of choice in<strong> Zollinger&ndash;Ellison syndrome.</strong>&nbsp;</p>\n<p>Zollinger Ellison syndrome includes pancreatic or duodenal <strong>gastrinoma</strong> which leads to the <strong>secretion</strong> of large amounts of <strong>gastrin.</strong> This, in turn, <strong>increases</strong> gastric <strong>acid</strong> leading to severe <strong>gastroduodenal ulceration</strong> and other effects of <strong>hyperchlorhydria.</strong></p>\n<p>Note: Netazepide is a gastrin/cholecystokinin-2 receptor antagonist used in the treatment of gastrinoma. It&nbsp;is also an antisecretory agent.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6548",
      "difficulty": "easy"
    },
    {
      "text": "A 60-year-old woman with osteoarthritis developed gastric ulcers following long-term use of NSAIDs. Of the following, which drug is FDA-approved for her condition?",
      "choices": [
        {
          "id": 1,
          "text": "PGE-1 analogue"
        },
        {
          "id": 2,
          "text": "PGD-2 antagonist"
        },
        {
          "id": 3,
          "text": "PGD-2 agonist"
        },
        {
          "id": 4,
          "text": "PGF-2 analogue"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>PGE<sub>1&nbsp;</sub>analog</strong> (misoprostol) is approved by the FDA for<strong>&nbsp;NSAID-induced gastric ulcers. </strong>It&nbsp;reduces gastric acid secretion in a dose-dependent manner.</p>\n<p>Prostaglandins <strong>inhibit gastric acid secretion.</strong> Misoprostol also increases mucosal blood flow and stimulates bicarbonate and mucin secretion which contribute to its <strong>cytoprotective</strong> action. However, the reduction in acid secretion is less than that of H<sub>2</sub> blockers.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6531",
      "difficulty": "easy"
    },
    {
      "text": "What is the most effective therapy for NSAID-induced ulcers?",
      "choices": [
        {
          "id": 1,
          "text": "Antacids"
        },
        {
          "id": 2,
          "text": "H2 blockers"
        },
        {
          "id": 3,
          "text": "Misoprostol"
        },
        {
          "id": 4,
          "text": "Proton pump inhibitors"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The most effective therapy for <strong>NSAID-induced ulcers</strong> is <strong>proton pump inhibitors.&nbsp;</strong></p>\n<p>They are proven to be more effective than misoprostol and H2 receptor antagonists.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6535",
      "difficulty": "medium"
    },
    {
      "text": "Which proton pump inhibitor should be avoided in a patient on warfarin anticoagulation?",
      "choices": [
        {
          "id": 1,
          "text": "Rabeprazole"
        },
        {
          "id": 2,
          "text": "Pantoprazole"
        },
        {
          "id": 3,
          "text": "Lansoprazole"
        },
        {
          "id": 4,
          "text": "Omeprazole"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Omeprazole</strong>&nbsp;should not be used in a patient on warfarin therapy as it&nbsp;<strong>decreases</strong> the<strong> metabolism</strong> of<strong> warfarin</strong>.&nbsp;</p>\n<div class=\"page\" title=\"Page 1109\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>All PPIs are metabolized by hepatic P450 cytochromes, including CYP2C19 and CYP3A4, and may interfere with the metabolism of the other drugs.&nbsp;It&nbsp;<strong>inhibits </strong>the <strong>metabolism</strong> of <strong>clopidogrel, diazepam,</strong> and <strong>phenytoin.</strong></p>\n</div>\n</div>\n</div><p>Note:&nbsp;There is disagreement among different authors regarding the PPIs and their interactions with the metabolism of other drugs.</p>\n<ul>\n<li>Goodman and Gilman mention that&nbsp;lansoprazole and rabeprazole along with omeprazole and esomeprazole interact with the metabolism of warfarin.</li>\n<li>Katzung and various online sources agree that lansoprazole and rabeprazole do not or minimally interact with warfarin metabolism.</li>\n<li>All of them agree that pantoprazole does not or minimally interacts with warfarin metabolism.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1311",
      "difficulty": "medium"
    },
    {
      "text": "You are counseling a patient with gastroesophageal reflux disease about the need for long-term therapy with proton-pump inhibitors. All of the following are complications of this therapy, except:",
      "choices": [
        {
          "id": 1,
          "text": "Decreased vitamin B12 absorption"
        },
        {
          "id": 2,
          "text": "Increased susceptibility to infections"
        },
        {
          "id": 3,
          "text": "Hypogastrinemia"
        },
        {
          "id": 4,
          "text": "Increased risk of bone fracture"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Long-term PPI therapy</strong> is not associated with hypogastrinemia but is associated with <strong>hypergastrinemia</strong>. This hypergastrinemia contributes to <strong>rebound gastric acid hypersecretion</strong> if PPI therapy is discontinued.</p>\n<p>Chronic PPI therapy is associated with:&nbsp;</p>\n<ul>\n<li>Decreased vitamin B12 absorption</li>\n<li>Increased susceptibility to infections-&nbsp;hospital-acquired pneumonia, pseudomembranous enterocolitis</li>\n<li>Reduced calcium absorption increases the risk of fractures</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6525",
      "difficulty": "medium"
    },
    {
      "text": "Gynecomastia can occur as a side effect of:",
      "choices": [
        {
          "id": 1,
          "text": "Aluminium hydroxide"
        },
        {
          "id": 2,
          "text": "Cimetidine"
        },
        {
          "id": 3,
          "text": "Pirenzepine"
        },
        {
          "id": 4,
          "text": "Lansoprazole"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Gynecomastia</strong> can occur as a side effect of <strong>cimetidine.</strong>&nbsp;It inhibits the binding of dihydrotestosterone to androgen receptors, increases the serum prolactin level and inhibits the metabolism of estradiol by the liver. Cimetidine causes maximum hepatic inhibition.&nbsp;</p>\n<p>The <strong>specific side effect&nbsp;</strong>of high doses of cimetidine given for a long time is <strong>gynecomastia</strong> or<strong> impotence </strong>in males and<strong> galactorrhea </strong>in females. This property is not shared by other H2 blockers.</p>\n<p><strong>Drugs causing gynecomastia:</strong></p>\n<ul>\n<li>Alcohol, marijuana, heroin</li>\n<li>Antiretroviral therapy</li>\n<li>Anabolic steroids</li>\n<li>Digoxin</li>\n<li>Risperidone</li>\n<li>Ketoconazole</li>\n<li>Spironolactone</li>\n<li>&alpha;-methyldopa</li>\n<li>Bromocriptine</li>\n<li>Cimetidine</li>\n<li>Phenytoin therapy.&nbsp;</li>\n<li>Androgens- testosterone and its esters (except dihydrotestosterone).&nbsp;</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6527",
      "difficulty": "easy"
    },
    {
      "text": "A patient with peptic ulcer disease was prescribed ranitidine and sucralfate to be taken together. Why is this combination incorrect?",
      "choices": [
        {
          "id": 1,
          "text": "Ranitidine combines with sucralfate and forms a toxic metabolite"
        },
        {
          "id": 2,
          "text": "Sucralfate competes with ranitidine for H2 receptor"
        },
        {
          "id": 3,
          "text": "Ranitidine increases the gastric pH which reduces sucralfate efficacy"
        },
        {
          "id": 4,
          "text": "Sucralfate inhibits the absorption of ranitidine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Ranitidine increases</strong> the <strong>gastric pH</strong> (i.e. less acidic) which <strong>reduces</strong> <strong>sucralfate efficacy;</strong> hence the combination is incorrect.&nbsp;</p>\n<p><strong>Polymerization </strong>of sucralfate occurs only at an<strong> acidic pH</strong> by crosslinking of the molecules which forms a sticky gel-like consistency. This adheres to the ulcer base predominantly and remains there for almost 6 hours, <strong>preventing</strong> the <strong>ulcer</strong> base from coming in <strong>contact</strong> with the <strong>acid.</strong>&nbsp;</p>\n<p>Concurrent use of <strong>H2 blockers </strong>like ranitidine <strong>increases</strong> the gastric<strong> pH </strong>and thus<strong> hinders </strong>the <strong>polymerization </strong>and reduces the efficacy of sucralfate.&nbsp;</p>\n<p>Sucralfate should be taken at least 2 hours after the administration of any other drug.</p><p>Note: The FDA has requested the <strong>withdrawal </strong>of all<strong> ranitidine </strong>products from the market due to the presence of a contaminant NDMA which is a probable human <strong>carcinogen</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6533",
      "difficulty": "medium"
    },
    {
      "text": "Gastric bezoars are commonly associated with __________.",
      "choices": [
        {
          "id": 1,
          "text": "Proton pump inhibitors"
        },
        {
          "id": 2,
          "text": "H2 blockers"
        },
        {
          "id": 3,
          "text": "Misoprostol"
        },
        {
          "id": 4,
          "text": "Sucralfate"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Gastric bezoars</strong> are commonly associated with <strong>sucralfate.</strong>&nbsp;</p>\n<p>Sucralfate produces a viscous gel that has a &lsquo;<strong>sticky nature</strong>&rsquo;. The sticky nature may be responsible for the formation of gastric bezoars, particularly in those with<strong> gastroparesis.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6534",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a characteristic of milk-alkali syndrome?",
      "choices": [
        {
          "id": 1,
          "text": "Alkalosis"
        },
        {
          "id": 2,
          "text": "Renal insufficiency"
        },
        {
          "id": 3,
          "text": "Hypercalcemia"
        },
        {
          "id": 4,
          "text": "Hepatotoxicity"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Milk alkali syndrome is not characterized by hepatotoxicity.</p>\n<p><strong>Characteristics</strong> of the <strong>milk-alkali</strong> syndrome include:</p>\n<ul>\n<li>Alkalosis</li>\n<li>Hypercalcemia</li>\n<li>Renal insufficiency</li>\n</ul>\n<p>Milk alkali syndrome used to occur in patients who were administered <strong>high doses</strong> of <strong>NaHCO<sub>3</sub></strong> and <strong>CaCO<sub>3</sub></strong> along with <strong>milk</strong> or cream for the management of peptic ulcers.</p>\n<p>The syndrome is rare now and generally occurs with a large intake of calcium supplements along with milk.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6537",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following can cause diarrhea?",
      "choices": [
        {
          "id": 1,
          "text": "Sodium bicarbonate"
        },
        {
          "id": 2,
          "text": "Magnesium hydroxide"
        },
        {
          "id": 3,
          "text": "Calcium bicarbonate"
        },
        {
          "id": 4,
          "text": "Aluminium hydroxide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Magnesium salts</strong> have a <strong>laxative</strong> property and can cause <strong>diarrhoea</strong>.</p>\n<p><strong>Aluminium salts</strong> can cause <strong>constipation</strong> by relaxing smooth muscles.&nbsp;</p>\n<p>The<strong> combination</strong> of aluminium and magnesium salts can <strong>neutralize </strong>each other&rsquo;s action, thus the combination is preferred.</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6538",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following antacids is more likely to induce rebound acid secretion?",
      "choices": [
        {
          "id": 1,
          "text": "Calcium carbonate"
        },
        {
          "id": 2,
          "text": "Magnesium hydroxide"
        },
        {
          "id": 3,
          "text": "Aluminium hydroxide"
        },
        {
          "id": 4,
          "text": "Sodium bicarbonate"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Calcium carbonate</strong> is an antacid that is <strong>more likely</strong> to induce <strong>rebound acid secretion</strong>.</p>\n<p>Calcium containing antacids like calcium carbonate rapidly and effectively neutralizes gastric acid. Calcium in antacids causes rebound acid secretion, hence it is given at frequent intervals to reduce the incidence of rebound acid secretion.</p>\n<p>Magnesium, aluminium and sodium-containing antacids are less likely to cause this phenomenon.</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1315",
      "difficulty": "hard"
    },
    {
      "text": "A patient presents with complaints of black stools and black coated tongue as shown in the image. Which of the following drugs is implicated?",
      "choices": [
        {
          "id": 1,
          "text": "Sucralfate"
        },
        {
          "id": 2,
          "text": "Rasburicase"
        },
        {
          "id": 3,
          "text": "Colloidal bismuth subsalicylate"
        },
        {
          "id": 4,
          "text": "Simethicone"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Colloidal bismuth subsalicylate</strong> is known to cause <strong>blackening</strong> of the tongue, dentures and stools.</p>\n<p>It combines with trace amounts of sulfur in saliva and colon to form bismuth sulfide. Bismuth sulfide is a highly insoluble black salt. The adverse effect is claimed to be <strong>temporary</strong> and <strong>harmless</strong>.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b9206133a89a423db3a72bcca6e8937b.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1378",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is an antifoaming agent?",
      "choices": [
        {
          "id": 1,
          "text": "Sucralfate"
        },
        {
          "id": 2,
          "text": "Simethicone"
        },
        {
          "id": 3,
          "text": "Colloidal bismuth subcitrate"
        },
        {
          "id": 4,
          "text": "Rebamipide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Simethicone</strong> is a <strong>surfactant</strong> that <strong>decreases foaming. </strong>Due to this&nbsp;antifoaming action, it is included in many antacid preparations to <strong>reduce gastroesophageal reflux.</strong></p>\n<p>Option A:<strong>&nbsp;Sucralfate</strong> acts as an <strong>ulcer protective</strong> agent by forming a viscous sticky polymer that binds to the ulcer base.</p>\n<p>Option D: <strong>Rebamipide</strong> is also a <strong>cytoprotective</strong> agent that acts by increasing the production of prostaglandin in gastric mucosa and by scavenging reactive oxygen species.</p>\n<p>Option C: <strong>Bismuth compounds</strong> bind to the base of the ulcer, <strong>promote mucin</strong> and<strong> bicarbonate production.&nbsp;</strong>They&nbsp;have significant antibacterial action and are part of many anti-H.pylori regimens.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6539",
      "difficulty": "medium"
    },
    {
      "text": "A patient with a history of peptic ulcer underwent endoscopic evaluation. The biopsy image is shown below. Which of the following drugs is not used in treating this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Metronidazole"
        },
        {
          "id": 2,
          "text": "Proton pump inhibitors"
        },
        {
          "id": 3,
          "text": "Sucralfate"
        },
        {
          "id": 4,
          "text": "Bismuth compounds"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The image shows a<strong> Warthin silver starry stain</strong>ed biopsy specimen,<strong>&nbsp;</strong>diagnostic for&nbsp;<em><strong>Helicobacter pylori</strong>.&nbsp;</em><strong>Sucralfate</strong> does not have any anti-<em>H.&nbsp;pylori</em> action and is <strong>not used</strong> in the treatment of <em>H. pylori</em>&nbsp;gastritis.</p>\n<p>Option A: Metronidazole is used in the triple, quadruple therapy, and sequential therapy regimens.&nbsp;</p>\n<p>Option B: Proton pump inhibitors significantly enhance the effectiveness of regimens containing amoxicillin or clarithromycin.</p>\n<p>Option D: Bismuth compounds have significant anti-bacterial action and are given in quadruple therapy.</p>\n<p>Two or three antimicrobials are combined in regimens that range from 10-14 days. <strong>Monotherapy</strong> is <strong>not recommended</strong> due to the development of <strong>resistance.</strong></p><hr><h3>Related Pearl: H. pylori eradication regimen</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>1<sup>st</sup> line</strong></p>\n<p><strong>[OCA/OCM - 14 days]</strong></p>\n</td>\n<td>\n<p><strong>2<sup>nd</sup> line</strong></p>\n<p><strong>[TOMB - 14 days]</strong></p>\n</td>\n<td>\n<p><strong>3<sup>rd</sup> line /Clarithromycin-resistant cases </strong></p>\n<p><strong>[LOA - 10 days]</strong></p>\n</td>\n<td>\n<p><strong>Sequential Regimen</strong></p>\n<p><strong>[OA (5days) + OCT (5days)]</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>O</strong>meprazole</p>\n</td>\n<td><strong>T</strong>etracycline</td>\n<td><strong>L</strong>evofloxacin</td>\n<td><strong>O</strong>meprazole</td>\n</tr>\n<tr>\n<td><strong>C</strong>larithromycin</td>\n<td><strong>O</strong>meprazole</td>\n<td><strong>O</strong>meprazole</td>\n<td><strong>C</strong>larithromycin</td>\n</tr>\n<tr>\n<td><strong>A</strong>moxicillin/</td>\n<td><strong>M</strong>etronidazole</td>\n<td><strong>A</strong>moxicillin</td>\n<td><strong>A</strong>moxicillin</td>\n</tr>\n<tr>\n<td><strong>M</strong>etronidazole</td>\n<td><strong>B</strong>ismuth</td>\n<td>&nbsp;</td>\n<td><strong>T</strong>inidazole</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/4e5c85441ff74237bf75eabd85d8128d.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6540",
      "difficulty": "medium"
    },
    {
      "text": "A 30-year-old man presented with bloody diarrhea and abdominal pain for the past week. Pseudopolyps were noted on colonoscopy. Which of the following can be used in managing his condition?",
      "choices": [
        {
          "id": 1,
          "text": "Sulfasalazine"
        },
        {
          "id": 2,
          "text": "Sulfamethoxazole"
        },
        {
          "id": 3,
          "text": "Sulfinpyrazone"
        },
        {
          "id": 4,
          "text": "Sulphadoxine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Bloody diarrhea</strong> and colonoscopy findings of <strong>pseudopolyps</strong>&nbsp;are suggestive of <strong>ulcerative colitis.</strong>&nbsp;The sulfa drug indicated is&nbsp;<strong>sulfasalazine</strong>.</p>\n<p>It is indicated mainly in mild-moderate ulcerative colitis and as an adjunctive in severe cases. Efficacy in Crohn&rsquo;s disease is less.</p>\n<p>Sulfasalazine consists of <strong>5-ASA</strong> (mesalamine or 5-amino salicylic acid) <strong>linked</strong> to <strong>sulfapyridine</strong> with an <strong>azo bond.</strong> Individually, 5-ASA and sulfapyridine would be absorbed in the upper gastrointestinal tract, the azo bond prevents such absorption. Colonic bacteria break the azo bond to liberate sulfapyridine and 5-ASA. 5-ASA is considered to be the active moiety.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6574",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not a prodrug?",
      "choices": [
        {
          "id": 1,
          "text": "Sulfasalazine"
        },
        {
          "id": 2,
          "text": "Mesalamine"
        },
        {
          "id": 3,
          "text": "Balsalazide"
        },
        {
          "id": 4,
          "text": "Olsalazine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Mesalamine is not a prodrug. <strong>Mesalamine</strong> or 5-ASA is the <strong>active component</strong> that is responsible for the beneficial effects of inflammatory bowel disease. <strong><br /></strong><br /><strong>Cleavage</strong> of the <strong>bond</strong> of <strong>prodrugs</strong> that deliver mesalamine to the colon occurs by <strong>colonic bacteria.</strong></p>\n<p>Option A: Sulfasalazine - 5-ASA + sulfapyridine</p>\n<p>Option C: Balsalazide - 5-ASA + an inert compound</p>\n<p>Option D: Olsalazine - 5-ASA + 5-ASA</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1317",
      "difficulty": "medium"
    },
    {
      "text": "A patient with Crohn's disease, refractory to steroid therapy is planned to be started on an anti-TNF alpha monoclonal antibody. Which of the following drugs does not belong in this class?",
      "choices": [
        {
          "id": 1,
          "text": "Infliximab"
        },
        {
          "id": 2,
          "text": "Adalimumab"
        },
        {
          "id": 3,
          "text": "Certolizumab pegol"
        },
        {
          "id": 4,
          "text": "Vedolizumab"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Vedolizumab</strong> is a humanized <strong>anti-alpha-4-beta-7&nbsp;integrin</strong> <strong>monoclonal antibody</strong>&nbsp;that prevents lymphocyte recruitment to the intestinal mucosa.</p>\n<p>It is approved for use in moderate-severe <strong>Crohn's</strong> disease and <strong>ulcerative</strong> colitis.</p>\n<p><strong>Anti-TNF alpha</strong> monoclonal antibodies indicated in IBD are:&nbsp;</p>\n<ul>\n<li>Infliximab</li>\n<li>Adalimumab</li>\n<li>Certolizumab pegol</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1319",
      "difficulty": "medium"
    },
    {
      "text": "Which is not given in Wilson's disease?",
      "choices": [
        {
          "id": 1,
          "text": "Zinc"
        },
        {
          "id": 2,
          "text": "Penicillamine"
        },
        {
          "id": 3,
          "text": "Calcium citrate"
        },
        {
          "id": 4,
          "text": "Trientine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Calcium citrate is not used in the treatment of Wilson's disease.</p>\n<p>The drugs used in the management of Wilson's disease are:</p>\n<p><strong>Chelating agents</strong>: These drugs bind to copper to form complexes that get excreted in the urine. D-penicillamine and trientine are<strong> first-line</strong> drugs in symptomatic patients with hepatic diseases.</p>\n<ul>\n<li><strong>D-penicillamine</strong>: It is the recommended drug due to its availability and cost-effectiveness as compared to trientine. Since it is an antagonist to pyridoxine, supplementation of pyridoxine is required. It can precipitate various adverse effects including aplastic anemia, myasthenia gravis, and membranous nephropathy. It can also worsen neurological symptoms</li>\n<li><strong>Trientine</strong>: It is administered in those who cannot tolerate D-penicillamine</li>\n<li><strong>Tetrathiomolybdate</strong>: It has been identified to be effective in patients with neuropsychiatric manifestation</li>\n</ul>\n<p><strong>Elemental zinc</strong>:&nbsp;</p>\n<ul>\n<li aria-level=\"1\">Zinc blocks the intestinal absorption of copper by inducing metallothionein (endogenous chelator in enterocytes)</li>\n<li aria-level=\"1\">It is commonly used as a maintenance therapy along with chelating agents. It can also be used as first-line therapy in pregnancy</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0140",
      "difficulty": "medium"
    }
  ]
}